SODIUM PHOSPHATES monobasic monohydrate and dibasic anhydrous injection solution United States - English - NLM (National Library of Medicine)

sodium phosphates monobasic monohydrate and dibasic anhydrous injection solution

cardinal health - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr) - sodium phosphate, monobasic, monohydrate 276 mg in 1 ml

PEDIATRIC SALINE LAXATIVE- sodium phosphate, monobasic, unspecified form and sodium phosphate, dibasic enema United States - English - NLM (National Library of Medicine)

pediatric saline laxative- sodium phosphate, monobasic, unspecified form and sodium phosphate, dibasic enema

natureplex, llc - sodium phosphate, monobasic, unspecified form (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic, unspecified form (unii: gr686lba74) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - sodium phosphate, monobasic, unspecified form 3.5 g in 59 ml - - relieves occasional constipation - this product generally produces bowel movement in 1 to 5 minutes

Phosphate Phebra Australia - English - Department of Health (Therapeutic Goods Administration)

phosphate phebra

phebra pty ltd - monobasic sodium phosphate, quantity: 1.936 g - tablet, effervescent - excipient ingredients: potassium bicarbonate; citric acid; sucrose; macrogol 4000; saccharin sodium; sodium bicarbonate; flavour - 1) hypercalcaemia associated with such conditions as hyperparathyroidism, multiple myelomatosis, and metastatic bone disease.,2) hypophosphataemia associated with vitamin d resistant rickets.

SODIUM PHOSPHATES- sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous injection, solution United States - English - NLM (National Library of Medicine)

sodium phosphates- sodium phosphate, monobasic, monohydrate and sodium phosphate, dibasic, anhydrous injection, solution

fresenius kabi usa, llc - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (sodium cation - unii:lyr4m0nh37) - sodium phosphates injection, usp, 3 mm p/ml is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. the concomitant amount of sodium (na+ 4 meq/ml) must be calculated into total electrolyte dose of such prepared solutions. sodium phosphate is contraindicated in diseases where high phosphorus or low calcium levels may be encountered, and in patients with hypernatremia.

PHOSPHASAL- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate ta United States - English - NLM (National Library of Medicine)

phosphasal- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate ta

star pharmaceuticals, llc - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - sodium phosphate, monobasic, monohydrate 40.8 mg - phosphasal ™ tablets are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. hypersensitivity to any of the ingredients is possible. risk benefits should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis, acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of phosphasal ™ tablets has not been reported and due to the nature of its ingredients, abuse of phosphasal ™ tablets is not expected.

SODIUM PHOSPHATES INJECTION USP SOLUTION Canada - English - Health Canada

sodium phosphates injection usp solution

sandoz canada incorporated - sodium phosphate monobasic; sodium phosphate dibasic - solution - 276mg; 268mg - sodium phosphate monobasic 276mg; sodium phosphate dibasic 268mg - replacement preparations

Coloprep 1500 mg Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

coloprep 1500 mg tablets

laboratoires mayoly spindler - sodium phosphate monobasic; sodium phosphate dibasic, anhydrous - tablet - 1500 milligram(s) - osmotically acting laxatives; sodium phosphate

SODIUM PHOSPHATE SOFAR ‘16%/6% rectal solution’ 120 ml bottle Malta - English - Medicines Authority

sodium phosphate sofar ‘16%/6% rectal solution’ 120 ml bottle

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - sodium phosphate, monobasic dihydrate, dibasic heptahydrate - rectal solution - sodium phosphate monobasic dihydrate 16 g/100ml sodium phosphate dibasic heptahydrate 6 g/100ml - drugs for constipation

SODIUM VALPROATE WOCKHARDT sodium valproate 1000 mg/10 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

sodium valproate wockhardt sodium valproate 1000 mg/10 ml solution for injection ampoule

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

SODIUM VALPROATE WOCKHARDT sodium valproate 400 mg/4 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

sodium valproate wockhardt sodium valproate 400 mg/4 ml solution for injection ampoule

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.